EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Reservation and Start-Up Agreement • August 16th, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • England and Wales
THIS RESERVATION AND START-UP AGREEMENT (“Agreement”), effective as of the date of execution by the last party to sign below (the “Effective Date”) is by and between hVIVO Services Limited, a company registered in England (company registration number 02326557) whose registered office is at QMB Innovation Centre, 42 New Road, London E1 2AX, UK (“hVIVO”) and AIM ImmunoTech Inc., a company incorporated in Delaware, USA, whose registered office or principle place of business is at 2117 SW Highway 484 Ocala, FL 34473, USA (“Sponsor”).
Supplementary Agreement (II)Material Transfer and Research Agreement • August 16th, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
Further and pursuant to the Material Transfer and Research Agreement the Parties agree to extend the duration of the Agreement by a period of twenty-four (24) months until 31 May 2023. All other terms and conditions under the agreement shall remain unchanged.
Supplementary Agreement (II)Material Transfer and Research Agreement • August 16th, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
Further and pursuant to the Material Transfer and Research Agreement the Parties agree to extend the duration of the Agreement by a period of twenty-four (24) months until 31 May 2023. All other terms and conditions under the agreement shall remain unchanged.
